Risultati della ricerca - Shih‐Feng Cho

  • Mostra 1 - 14 risultati su 14
Raffina i risultati
  1. 1
    Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1

    Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1 di Yu‐Tzu Tai, Shih‐Feng Cho, Kenneth C. Anderson

    Pubblicazione 2018
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  2. 2
    Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy

    Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy di Shih‐Feng Cho, Kenneth C. Anderson, Yu‐Tzu Tai

    Pubblicazione 2018
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  3. 3
    Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma

    Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma di Hui‐Ching Wang, Leong‐Perng Chan, Shih‐Feng Cho

    Pubblicazione 2019
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  4. 4
    Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma

    Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma di Shih‐Feng Cho, Lijie Xing, Kenneth C. Anderson, Yu‐Tzu Tai

    Pubblicazione 2021
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  5. 5
    Bispecific antibodies in multiple myeloma treatment: A journey in progress

    Bispecific antibodies in multiple myeloma treatment: A journey in progress di Shih‐Feng Cho, Tsung‐Jang Yeh, Kenneth C. Anderson, Yu-Tzu Tai

    Pubblicazione 2022
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  6. 6
    BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma

    BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma di Shih‐Feng Cho, Liang Lin, Lijie Xing, Yuyin Li, Tengteng Yu, Kenneth C. Anderson, Yu‐Tzu Tai

    Pubblicazione 2020
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  7. 7
    Prognostic significance of total metabolic tumor volume on 18F-fluorodeoxyglucose positron emission tomography/ computed tomography in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy

    Prognostic significance of total metabolic tumor volume on 18F-fluorodeoxyglucose positron emission tomography/ computed tomography in patients with diffuse large B-cell lymphoma r... di Chin-Chuan Chang, Shih‐Feng Cho, Ya‐Wen Chuang, Chia-Yang Lin, Shu-Min Chang, Wen-Ling Hsu, Ying‐Fong Huang

    Pubblicazione 2017
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  8. 8
    MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression

    MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression di Shih‐Feng Cho, Yu-Li Chang, Chao‐Sung Chang, Sheng-Fung Lin, Yi‐Chang Liu, Hui‐Hua Hsiao, Jan‐Gowth Chang, Ta‐Chih Liu

    Pubblicazione 2014
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  9. 9
    A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma

    A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma di Lijie Xing, Liang Lin, Tengteng Yu, Yuyin Li, Shih‐Feng Cho, Jiye Liu, Kenneth Wen, Phillip A. Hsieh, Krista Kinneer, Nikhil C. Munshi, Kenneth C. Anderson, Yu‐Tzu Tai

    Pubblicazione 2020
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  10. 10
    γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation

    γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation di Hailin Chen, Tengteng Yu, Liang Lin, Lijie Xing, Shih‐Feng Cho, Kenneth Wen, Kimberly Aardalen, Adwait Oka, Joni Lam, Mike Daley, Haihui Lu, Nikhil C. Munshi, Kenneth C. Anderson, Yu‐Tzu Tai

    Pubblicazione 2022
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  11. 11
    APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications

    APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications di Yu‐Tzu Tai, Liang Lin, Lijie Xing, Shih‐Feng Cho, Tengteng Yu, Chirag Acharya, Kenneth Wen, Phillip A. Hsieh, John Dulos, Andrea van Elsas, Nikhil C. Munshi, Paul G. Richardson, Kenneth C. Anderson

    Pubblicazione 2018
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  12. 12
    The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models

    The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models di Shih‐Feng Cho, Liang Lin, Lijie Xing, Yuyin Li, Kenneth Wen, Tengteng Yu, Phillip A. Hsieh, Nikhil C. Munshi, Joachim Wahl, Katja Matthes, Matthias Friedrich, Tara Arvedson, Kenneth C. Anderson, Yu‐Tzu Tai

    Pubblicazione 2020
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  13. 13
    Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma

    Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma di Liang Lin, Shih‐Feng Cho, Lijie Xing, Kenneth Wen, Yuyin Li, Tengteng Yu, Phillip A. Hsieh, Hailin Chen, Metin Kurtoğlu, Yi Zhang, Charles A. Stewart, Nikhil C. Munshi, Kenneth C. Anderson, Yu‐Tzu Tai

    Pubblicazione 2020
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  14. 14
    VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo

    VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo di Tengteng Yu, Bharat K. R. Chaganty, Liang Lin, Lijie Xing, Boopathy Ramakrishnan, Kenneth Wen, Phillip A. Hsieh, Andrew M. Wollacott, Karthik Viswanathan, Hedy Adari, Shih‐Feng Cho, Yuyin Li, Hailin Chen, Wenjuan Yang, Yan Xu, Gang An, Lugui Qiu, Nikhil C. Munshi, Gregory J. Babcock, Zachary Shriver, James R. Myette, Kenneth C. Anderson, Yu‐Tzu Tai

    Pubblicazione 2020
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:

Strumenti per la ricerca: